Search Results - "Knop, F. K."

Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling by Knop, F. K

“…Certain types of bariatric surgical procedures have proved not only to be effective with regard to treating obesity, but they also seem to be associated with…”
Get full text

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies by Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., Knop, F. K.

“…Aims/hypothesis We carried out a systematic review of clinical studies investigating glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes…”
Get full text

N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor by Hansen, L S, Sparre‐Ulrich, A H, Christensen, M, Knop, F K, Hartmann, B, Holst, J J, Rosenkilde, M M

“…Background and Purpose Glucose‐dependent insulinotropic polypeptide (GIP) affects lipid, bone and glucose homeostasis. High‐affinity ligands for the GIP…”
Get full text

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes by Højberg, P. V, Vilsbøll, T, Rabøl, R, Knop, F. K, Bache, M, Krarup, T, Holst, J. J, Madsbad, S

“…Objective The incretin effect is attenuated in patients with type 2 diabetes mellitus, partly as a result of impaired beta cell responsiveness to…”
Get full text

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors by Sparre‐Ulrich, A H, Hansen, L S, Svendsen, B, Christensen, M, Knop, F K, Hartmann, B, Holst, J J, Rosenkilde, M M

“…Background and Purpose Specific, high potency receptor antagonists are valuable tools when evaluating animal and human physiology. Within the…”
Get full text

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity by Knop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., Madsbad, S.

“…Aims: People with type 2 diabetes mellitus (T2DM) are characterized by reduced incretin effect and inappropriate glucagon levels. We evaluated α and β‐cell…”
Get full text

Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects by Knop, F. K., Konings, E., Timmers, S., Schrauwen, P., Holst, J. J., Blaak, E. E.

“…Aims Resveratrol, a natural polyphenolic compound produced by various plants (e.g. red grapes) and found in red wine, has glucose‐lowering effects in humans…”
Get full text

Regulation of glucagon secretion by incretins by Holst, J. J., Christensen, M., Lund, A., de Heer, J., Svendsen, B., Kielgast, U., Knop, F. K.

“…Glucagon secretion plays an essential role in the regulation of hepatic glucose production, and elevated fasting and postprandial plasma glucagon…”
Get full text

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies by Bak, M. J., Wewer Albrechtsen, N. J., Pedersen, J., Knop, F. K., Vilsbøll, T., Jørgensen, N. B., Hartmann, B., Deacon, C. F., Dragsted, L. O., Holst, J. J.

“…Aims To evaluate the performances of commercially available glucagon‐like peptide‐1 (GLP‐1) assays and the implications for clinical studies. Methods Known…”
Get full text

Use of antibiotics in childhood and risk of Type 1 diabetes: a population‐based case–control study by Mikkelsen, K. H., Knop, F. K., Vilsbøll, T., Frost, M., Hallas, J., Pottegård, A.

“…Aims To investigate whether the use of antibiotics from infancy to adolescence influences the risk of Type 1 diabetes. Methods We conducted a population‐based…”
Get full text

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus by Knop, F. K, Vilsbøll, T, Madsbad, S, Holst, J. J, Krarup, T

“…Aims/hypothesis We investigated glucagon responses during OGTT and isoglycaemic i.v. glucose infusion, respectively, to further elucidate the mechanisms behind…”
Get full text

Reduced Glucose Tolerance and Insulin Resistance Induced by Steroid Treatment, Relative Physical Inactivity, and High-Calorie Diet Impairs the Incretin Effect in Healthy Subjects by Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., Knop, F. K.

“…Aims/Hypothesis: The loss of incretin effect in patients with type 2 diabetes mellitus may be secondary to impaired glucose homeostasis. We investigated…”
Get full text

The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide—Regardless of Etiology and Phenotype by Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T., Pedersen, O., Holst, J. J.

“…The effect of the insulinotropic incretin hormone, glucagon-like peptide-1 (GLP-1), is preserved in typical middle-aged, obese, insulin-resistant type 2…”
Get full text

Ghrelin secretion in humans – a role for the vagus nerve? by Veedfald, S., Plamboeck, A., Hartmann, B., Vilsbøll, T., Knop, F. K., Deacon, C. F., Svendsen, L. B., Holst, J. J.

“…Background Ghrelin, an orexigenic peptide, is secreted from endocrine cells in the gastric mucosa. Circulating levels rise in the preprandial phase, suggesting…”
Get full text

Decreased plasma chemerin levels in women with gestational diabetes mellitus by Hare, K. J., Bonde, L., Svare, J. A., Randeva, H. S., Asmar, M., Larsen, S., Vilsbøll, T., Knop, F. K.

“…Aims To evaluate fasting and post‐prandial serum chemerin levels in pregnant women with and without gestational diabetes, and again following delivery when…”
Get full text

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects by Rhee, N A, Østoft, S H, Holst, J J, Deacon, C F, Vilsbøll, T, Knop, F K

“…ObjectiveInhibition of dipeptidyl peptidase 4 (DPP4) is thought to intensify the physiological effects of the incretin hormones. We investigated the effects of…”
Get full text

Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus by Bonde, L., Vilsbøll, T., Nielsen, T., Bagger, J. I., Svare, J. A., Holst, J. J., Larsen, S., Knop, F. K.

“…Aim We investigated postprandial glucagon‐like peptide‐1 (GLP‐1) responses in pregnant women with and without gestational diabetes mellitus (GDM) and again…”
Get full text

Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial by Munch, L., Bennich, B. B., Overgaard, D., Konradsen, H., Middelfart, H., Kaarsberg, N., Knop, F. K., Vilsbøll, T., Røder, M. E.

“…Aim To evaluate whether management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care has noninferior HbA1c…”
Get full text

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes by Højberg, P. V, Zander, M, Vilsbøll, T, Knop, F. K, Krarup, T, Vølund, A, Holst, J. J, Madsbad, S

“…Aims/hypothesis The ability of glucagon-like peptide-1 (GLP-1) to enhance beta cell responsiveness to i.v. glucose is impaired in patients with type 2 diabetes…”
Get full text

Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele by Færch, K., Pilgaard, K., Knop, F. K., Hansen, T., Pedersen, O., Jørgensen, T., Holst, J. J.

“…We characterised 62 non‐diabetic, middle‐aged, Caucasians with and without the T risk allele of rs7903146 in transcription factor 7‐like 2 (TCF7L2) with regard…”
Get full text